NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd
Post# of 122
BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company today congratulated its co-lead scientific research collaborator Professor Dr. Dirk Görlich, director at the Max Planck Institute for Multidisciplinary Sciences (“MPI”), on being awarded the inaugural $1.4 million World Laureates Association (“WLA”) Prize in Life Sciences or Medicine for his seminal work describing protein transport within the cell. “On behalf of BiondVax’s team, I wish to offer my sincere congratulations to Dirk on being awarded the inaugural WLA Prize in Life Sciences. The award signals recognition and appreciation of his important research achievements and deep scientific acumen,” said Amir Reichman, BiondVax’s CEO. “His expertise extends to the unique and innovative NanoAb candidates being developed under our collaboration. We look forward to forging ahead together with Dirk, Matthias and their teams as we strive to bring a pipeline of NanoAb therapies that exhibit significant competitive advantages for conditions underserved by currently approved therapeutics.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer